Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion,

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2
Recruiting	`NCT05281406` - Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)	Phase 2
Active, not recruiting	`NCT04223596` - Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients	Phase 2
Not yet recruiting	`NCT06374160` - Exercise in Patients With Advanced Non-small Cell Lung Cancer	N/A
Recruiting	`NCT05652868` - Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer	Phase 1
Completed	`NCT00198432` - Chemoradiotherapy of NSCLC Stage IIIB	Phase 2
Withdrawn	`NCT05212922` - A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	Phase 2
Active, not recruiting	`NCT04932343` - Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
Withdrawn	`NCT03231475` - Phase I Study of SPH1188-11 in NSCLC	Phase 1
Withdrawn	`NCT03628144` - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04865250` - Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC	Phase 2
Active, not recruiting	`NCT05816499` - Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)	Phase 1/Phase 2
Active, not recruiting	`NCT03620669` - 1st Line Durvalumab in PS 2 NSCLC Patients	Phase 2
Not yet recruiting	`NCT03594682` - Optimizing the Therapeutic Dose of Apatinib Mesylate Tablets in Patients With Lung Cancer by Dose Titration：A Real World Exploratory Study	N/A
Completed	`NCT03515252` - Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer	Phase 1

NCT number	NCT03805841
Study type	Interventional
Source	Rain Oncology Inc
Contact
Status	Terminated
Phase	Phase 2
Start date	March 13, 2019
Completion date	April 23, 2021

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions — RAIN

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms